Vascular endothelial growth factor receptor 3 antagonists - Pipeline Insight, 2022
![](/report_cover/8047/vascular-endothelial-growth-factor-receptor-3-antagonists-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Vascular endothelial growth factor receptor 3 antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Vascular endothelial growth factor receptor 3 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vascular endothelial growth factor receptor 3 antagonists: Overview
Vascular endothelial growth factor receptor 3 (VEGFR-3) binds VEGF-C and VEGF-D and is essential for the development of the lymphatic vasculature. Experimental tumors that overexpress VEGFR-3 ligands induce lymphatic vessel sprouting and enlargement and show enhanced metastasis to regional lymph nodes and beyond, whereas a soluble form of VEGFR-3 that blocks receptor signaling inhibits these changes and metastasis. VEGFR-3 is also essential for the early blood vessel development in embryos and is up-regulated in tumor angiogenesis. A number of different strategies to inhibit VEGF signal transduction are in development and they include the development of humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants, and inhibitors of VEGF receptor function. These agents can be divided in two broad classes, namely agents designed to target the VEGF activity and agents designed to target the surface receptor function.
Report Highlights
This segment of the Vascular endothelial growth factor receptor 3 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular endothelial growth factor receptor 3 antagonists Emerging Drugs
Further product details are provided in the report……..
Vascular endothelial growth factor receptor 3 antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Vascular endothelial growth factor receptor 3 antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Vascular endothelial growth factor receptor 3 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular endothelial growth factor receptor 3 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular endothelial growth factor receptor 3 antagonists drugs.
Vascular endothelial growth factor receptor 3 antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Vascular endothelial growth factor receptor 3 antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Vascular endothelial growth factor receptor 3 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vascular endothelial growth factor receptor 3 antagonists: Overview
Vascular endothelial growth factor receptor 3 (VEGFR-3) binds VEGF-C and VEGF-D and is essential for the development of the lymphatic vasculature. Experimental tumors that overexpress VEGFR-3 ligands induce lymphatic vessel sprouting and enlargement and show enhanced metastasis to regional lymph nodes and beyond, whereas a soluble form of VEGFR-3 that blocks receptor signaling inhibits these changes and metastasis. VEGFR-3 is also essential for the early blood vessel development in embryos and is up-regulated in tumor angiogenesis. A number of different strategies to inhibit VEGF signal transduction are in development and they include the development of humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants, and inhibitors of VEGF receptor function. These agents can be divided in two broad classes, namely agents designed to target the VEGF activity and agents designed to target the surface receptor function.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vascular endothelial growth factor receptor 3 antagonists R&D. The therapies under development are focused on novel approaches for Vascular endothelial growth factor receptor 3 antagonists.
This segment of the Vascular endothelial growth factor receptor 3 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular endothelial growth factor receptor 3 antagonists Emerging Drugs
- Nintedanib: Boehringer Ingelheim
- Lenvatinib: Eisai
Further product details are provided in the report……..
Vascular endothelial growth factor receptor 3 antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Vascular endothelial growth factor receptor 3 antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Vascular endothelial growth factor receptor 3 antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Vascular endothelial growth factor receptor 3 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular endothelial growth factor receptor 3 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular endothelial growth factor receptor 3 antagonists drugs.
Vascular endothelial growth factor receptor 3 antagonists Report Insights
- Vascular endothelial growth factor receptor 3 antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Vascular endothelial growth factor receptor 3 antagonists drugs?
- How many Vascular endothelial growth factor receptor 3 antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular endothelial growth factor receptor 3 antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular endothelial growth factor receptor 3 antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular endothelial growth factor receptor 3 antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Boehringer Ingelheim
- Eisai
- HUTCMED
- Advenchen Laboratories
- Mirati Therapeutics
- Pfizer
- AiViva BioPharma
- Aerie Pharmaceuticals
- Avalyn Pharmaceuticals
- Xspray Pharma
- Lynkcell
- Bayer
- Metagone Biotech
- Chipscreen Biosciences
- Jiangsu Hengrui Medicine
- Roche
- AstraZeneca
- Loxo oncology
- Clearside Biomedical
- Nintedanib
- Lenvatinib
- LOXO 292
- AZD-2171
- CLS 1002
- Surufatinib
- Catequentinib
- Sitravatinib
- Axitinib
- AIV 007
- AR-14034
- AP02
- HyNap-Sora
- Pazopanib intravitreal
- LYN 00101
- BAY-57-9352
- SHR 1020
- MG D 1609
- CS-2164
Introduction
Executive Summary
Vascular endothelial growth factor receptor 3 antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vascular endothelial growth factor receptor 3 antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Nintedanib: Boehringer Ingelheim
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Telatinib: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
CLS 1002: Clearside Biomedical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
HyNap-Sora: Xspray Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular endothelial growth factor receptor 3 antagonists Key Companies
Vascular endothelial growth factor receptor 3 antagonists Key Products
Vascular endothelial growth factor receptor 3 antagonists- Unmet Needs
Vascular endothelial growth factor receptor 3 antagonists- Market Drivers and Barriers
Vascular endothelial growth factor receptor 3 antagonists- Future Perspectives and Conclusion
Vascular endothelial growth factor receptor 3 antagonists Analyst Views
Vascular endothelial growth factor receptor 3 antagonists Key Companies
Appendix
Executive Summary
Vascular endothelial growth factor receptor 3 antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vascular endothelial growth factor receptor 3 antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Nintedanib: Boehringer Ingelheim
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Telatinib: Bayer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
CLS 1002: Clearside Biomedical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
HyNap-Sora: Xspray Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular endothelial growth factor receptor 3 antagonists Key Companies
Vascular endothelial growth factor receptor 3 antagonists Key Products
Vascular endothelial growth factor receptor 3 antagonists- Unmet Needs
Vascular endothelial growth factor receptor 3 antagonists- Market Drivers and Barriers
Vascular endothelial growth factor receptor 3 antagonists- Future Perspectives and Conclusion
Vascular endothelial growth factor receptor 3 antagonists Analyst Views
Vascular endothelial growth factor receptor 3 antagonists Key Companies
Appendix